Back to Search
Start Over
Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
- Source :
- Cancer Medicine, Vol 9, Iss 16, Pp 5899-5907 (2020), Cancer Medicine
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Background This study aimed to evaluate the efficacy and safety of apatinib with a low dose of 250 mg/d in the treatment of platinum‐resistant or platinum‐refractory ovarian cancer patients. Methods Patients with platinum‐resistant or platinum‐refractory ovarian carcinoma treated with 250 mg/d apatinib in our institution from November 2016 to December 2017 were retrospectively reviewed. The tumor response and progression were evaluated according to the standard by incorporating the levels of CA125 and Response Evaluation Criteria in Solid Tumors 1.1. CTCAE 4.03 was used to evaluate adverse events (AEs). Results Fifty‐two eligible patients were enrolled in per‐protocol (PP) analysis and 65 patients (including 13 lost to follow‐up) were included in the intention‐to‐treat (ITT) analysis. In PP analysis, 18 patients (34.6%) had partial response (PR), 22 patients (42.3%) had stable disease (SD), and the disease control rate (DCR) was 61.5%. Median progression‐free survival (PFS) was 4.0 months (95% CI, 2.83‐5.17 m), and median overall survival (OS) was 25.33 months (95% CI, 17.74‐32.92 m). The objective response rate and DCR for patients in ITT analysis were 27.7% and 49.2%, respectively. The top three treatment‐related AEs were hypertension, hand‐foot syndrome, and leukopenia. Eight patients (15.4%) in PP population had grade 3 treatment‐related AEs. Previous chemotherapy lines, number of recurrences, and AEs did not affect the efficacy of apatinib. Age older than 60 was associated with higher rates of disease control and prolonged PFS (P<br />Apatinib 250 mg/day is a feasible treatment in patients with platinum‐resistant or platinum‐refractory EOC.
- Subjects :
- epithelial ovarian cancer
0301 basic medicine
Cancer Research
Pyridines
medicine.medical_treatment
Platinum Compounds
Single Center
Gastroenterology
platinum‐resistant
chemistry.chemical_compound
0302 clinical medicine
Apatinib
Original Research
Ovarian Neoplasms
education.field_of_study
Leukopenia
Age Factors
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Progression-Free Survival
Intention to Treat Analysis
Oncology
Response Evaluation Criteria in Solid Tumors
030220 oncology & carcinogenesis
Hypertension
Disease Progression
Female
Hand-Foot Syndrome
medicine.symptom
Adult
medicine.medical_specialty
Population
Antineoplastic Agents
lcsh:RC254-282
03 medical and health sciences
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Adverse effect
education
Aged
Retrospective Studies
Chemotherapy
business.industry
Membrane Proteins
Clinical Cancer Research
medicine.disease
angiogenesis inhibitor
030104 developmental biology
chemistry
Drug Resistance, Neoplasm
low dose
CA-125 Antigen
Feasibility Studies
business
Ovarian cancer
apatinib
Subjects
Details
- ISSN :
- 20457634
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....e8999e14e52cabce35121c2c43a32eeb